Arpit Davé, a seasoned Indian American technology and information leader in the biotechnology sector, has been appointed Executive Vice President and Chief Digital and Information Officer at BioMarin Pharmaceutical Inc., effective January 12, 2026. The appointment was announced in a Jan. 12, 2026 press release from the San Rafael, California‑based company, positioning Davé as a senior leader tasked with shaping the company’s enterprise technology and digital strategies at a time when digital innovation and data science are rapidly redefining biopharmaceutical research and development.
BioMarin, a global leader in developing and commercializing therapies for rare genetic diseases, created the Chief Digital and Information Officer role to accelerate its digital transformation initiatives across research, operations, and commercial functions. Reporting directly to President and Chief Executive Officer Alexander Hardy, Davé joins the BioMarin Leadership Team with a mandate to build and execute strategic roadmaps that leverage cutting‑edge technology, artificial intelligence, and data science to improve patient outcomes, operational efficiency, and enterprise adaptability.
Davé comes to BioMarin with more than two decades of experience in technology leadership roles within the biopharmaceutical and life sciences industries. His career includes senior technology executive positions at Amgen Inc., where he spent seven and a half years leading digital transformation and AI‑driven initiatives, as well as leadership roles at Bristol Myers Squibb and Merck. His professional background reflects a blend of information technology, digital strategy, data science, and innovation – skills that align with BioMarin’s vision of integrating advanced digital capabilities into its core business functions.
The appointment of an Indian American to a top leadership role in a major U.S. biotechnology company underscores both the growing presence of South Asian American executives in corporate leadership and the increasing importance of digital leadership within the life sciences sector. As Chief Digital and Information Officer, Davé will play a pivotal role in steering BioMarin’s technology investments, scaling digital initiatives that support drug discovery and development, and fostering collaborations that bridge traditional life science approaches with emerging digital paradigms.
In announcing the appointment, BioMarin emphasized Davé’s track record of using technology to solve complex business and scientific challenges. His work is expected to drive forward BioMarin’s digital transformation efforts, which encompass everything from data analytics and machine learning applications to enterprise IT modernization and cross‑functional integration. With rare disease-focused therapies often requiring complex research infrastructures and patient data insights, digital leadership in biotech has become increasingly strategic to competitive success and mission delivery in the industry.
Davé’s educational foundation includes a Master of Science in Industrial Engineering from the University of Texas and a Bachelor of Science in Mechanical Engineering from S.P. University in India, reflecting the global and interdisciplinary roots that have shaped his professional journey. His transition to BioMarin is poised to advance both the company’s technology agenda and the broader narrative of Indian American leadership in science‑driven corporate environments.
As digital transformation continues to reshape the biopharmaceutical landscape, leaders like Davé exemplify the strategic intersection of technical expertise and executive decision‑making. BioMarin’s investment in this role reflects a broader industry trend toward prioritizing digital capabilities as central drivers of innovation, operational resilience, and competitive advantage.
Key Takeaways About Arpit Davé
- Indian American technology executive appointed EVP and Chief Digital and Information Officer at BioMarin.
- Brings more than 20 years of digital strategy and IT leadership in biopharma.
- Leads digital transformation efforts at a rare disease biotech company.
- Role underscores importance of digital leadership in life sciences.
- Appointment reflects broader growth of South Asian American leaders in U.S. corporate biotech.
